| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
PCLX-001 targets N-myristoyltransferase (NMT), specifically both NMT1 and NMT2 isoforms. NMT is an enzyme that catalyzes the attachment of myristic acid to the N-terminus of proteins, a process known as myristoylation. This modification is essential for the function of many proteins involved in cell signaling, including proteins in the B-cell receptor (BCR) pathway. By inhibiting NMT, PCLX-001 disrupts protein myristoylation and inhibits BCR signaling, leading to anti-tumor activity in B-cell malignancies.
|
|---|---|
| ln Vitro |
In vitro, PCLX-001 inhibits NMT1 and NMT2 with IC50 values of 5 nM and 8 nM, respectively. It exhibits anti-tumor activity and inhibits early B-cell receptor (BCR) signaling. The compound's inhibition of NMT prevents myristoylation of key signaling proteins, disrupting BCR signaling and leading to anti-proliferative effects in B-cell malignancies. These in vitro activities make PCLX-001 a promising candidate for B-cell malignancy research.
|
| ln Vivo |
In vivo, PCLX-001 is orally active and has shown anti-tumor activity in preclinical models. It inhibits early B-cell receptor (BCR) signaling and can be used for B-cell malignancies research. Specific in vivo efficacy data are limited in publicly available sources. The compound is primarily used as a research tool for studying NMT and BCR signaling.
|
| Enzyme Assay |
In vitro enzyme assays for NMT inhibition are used to characterize PCLX-001's activity. NMT1 and NMT2 enzymes are incubated with the compound, myristoyl-CoA, and a peptide substrate. Myristoylation is measured by incorporation of labeled myristate or by mass spectrometry. IC50 values of 5 nM (NMT1) and 8 nM (NMT2) are determined from dose-response curves.
|
| Cell Assay |
Cell-based assays for PCLX-001 are conducted in B-cell malignancy cell lines. Cells are treated with the compound at various concentrations, and BCR signaling is assessed by measuring phosphorylation of downstream signaling molecules. Cell proliferation and apoptosis are measured by standard assays. These assays characterize the compound's anti-tumor activity.
|
| Animal Protocol |
In vivo animal experiments with PCLX-001 are conducted in xenograft models of B-cell malignancies. The compound is administered orally, and tumor growth inhibition is assessed. BCR signaling and NMT inhibition are evaluated in tumor tissues. Specific protocols are not extensively documented.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of PCLX-001 include oral activity and good oral bioavailability. The compound has molecular weight 537.51 and molecular formula C24H30Cl2N6O2S. Solubility: DMSO and alcohol. Storage: appropriately. Specific PK parameters have not been extensively reported.
|
| Toxicity/Toxicokinetics |
Safety and toxicology data for PCLX-001 are limited. The compound is for research use only and is not approved for human therapeutic use. Standard laboratory safety precautions should be followed when handling the compound. The compound should be stored properly and disposed of in accordance with applicable regulations.
|
| Additional Infomation |
PCLX-001 is a first-in-class N-myristyltransferase (NMT) inhibitor developed by Pacylex Pharmaceuticals. Existing research indicates that PCLX-001's mechanism of action differs from other known anticancer drugs, demonstrating high activity and positive efficacy in breast, lung, bladder, and pancreatic cancers. Zelenirstat is an orally bioavailable N-myristyltransferase (NMT) inhibitor with potential antitumor activity. After oral administration, Zelenirstat targets and binds to NMT, particularly NMT2. This blocks NMT-mediated signaling and myristylation, thereby inhibiting the proliferation of certain NMT-deficient cancer cells. Zelenirstat also inhibits B-cell receptor (BCR) signaling and reduces the level of Src family tyrosine kinases (SFK). NMTs mediate myristylation, a crucial process through which the fatty acid myristate is added to proteins, enabling them to interact with cell membranes and become part of the cell signaling system. NMT expression is absent in various cancers, such as leukemia cells, which are therefore more sensitive to zelenizal compared to normal cells. The absence of NMT expression may promote tumorigenesis.
PCLX-001 has CAS number 1215011-08-7, molecular formula C24H30Cl2N6O2S, and molecular weight 537.51. Synonyms: DDD86481. It is an orally active NMT inhibitor with IC50s of 5 nM (NMT1) and 8 nM (NMT2). It exhibits anti-tumor activity and inhibits early BCR signaling. Purity: ≥97%. Not for human use; for research purposes only. |
| Molecular Formula |
C24H30CL2N6O2S
|
|---|---|
| Molecular Weight |
537.505001544952
|
| Exact Mass |
536.152
|
| CAS # |
1215011-08-7
|
| Related CAS # |
1215011-08-7;DDD86481 Tosylate;
|
| PubChem CID |
58561243
|
| Appearance |
Off-white to light yellow solid powder
|
| LogP |
4.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
781
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
WKTSLVQYGBHNRV-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H30Cl2N6O2S/c1-15(2)11-21-23(16(3)31(4)29-21)30-35(33,34)24-19(25)12-18(13-20(24)26)17-5-6-28-22(14-17)32-9-7-27-8-10-32/h5-6,12-15,27,30H,7-11H2,1-4H3
|
| Chemical Name |
2,6-dichloro-N-[1,5-dimethyl-3-(2-methylpropyl)pyrazol-4-yl]-4-(2-piperazin-1-ylpyridin-4-yl)benzenesulfonamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~10 mg/mL (~18.60 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1 mg/mL (1.86 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 400 μL of PEG300 and mix evenly; then add 50 μL of Tween-80 to the above solution and mix evenly; then add 450 μL of normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1 mg/mL (1.86 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 10.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1 mg/mL (1.86 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.8604 mL | 9.3022 mL | 18.6043 mL | |
| 5 mM | 0.3721 mL | 1.8604 mL | 3.7209 mL | |
| 10 mM | 0.1860 mL | 0.9302 mL | 1.8604 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
